{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T16:15:40Z","timestamp":1775924140140,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"the National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2022R1A2C2006746"],"award-info":[{"award-number":["2022R1A2C2006746"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06060-9","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:02:38Z","timestamp":1730851358000},"page":"5261-5272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beneficial effects of cellular immunotherapy in the prevention and treatment of posttransplant hematologic relapse of myelodysplastic neoplasms"],"prefix":"10.1007","volume":"103","author":[{"given":"Gi-June","family":"Min","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-2956","authenticated-orcid":false,"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"6060_CR1","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I et al (2017) Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 129:1753\u20131762. https:\/\/doi.org\/10.1182\/blood-2016-06-724500","journal-title":"Blood"},{"key":"6060_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","volume":"28","author":"Z Lim","year":"2010","unstructured":"Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A et al (2010) Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 28:405\u2013411. https:\/\/doi.org\/10.1200\/JCO.2009.21.8073","journal-title":"J Clin Oncol"},{"key":"6060_CR3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M (2020) Myelodysplastic syndromes. N Engl J Med 383:1358\u20131374. https:\/\/doi.org\/10.1056\/NEJMra1904794","journal-title":"N Engl J Med"},{"key":"6060_CR4","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3324\/haematol.2014.105981","volume":"99","author":"C Oudin","year":"2014","unstructured":"Oudin C, Chevallier P, Furst S, Guillaume T, El Cheikh JE, Delaunay J et al (2014) Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. Haematologica 99:1762\u20131768. https:\/\/doi.org\/10.3324\/haematol.2014.105981","journal-title":"Haematologica"},{"key":"6060_CR5","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","volume":"27","author":"O Ringd\u00e9n","year":"2009","unstructured":"Ringd\u00e9n O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al (2009) Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 27:4570\u20134577. https:\/\/doi.org\/10.1200\/JCO.2008.20.9692","journal-title":"J Clin Oncol"},{"key":"6060_CR6","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.v97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390\u20133400. https:\/\/doi.org\/10.1182\/blood.v97.11.3390","journal-title":"Blood"},{"key":"6060_CR7","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.20.03380","volume":"39","author":"R Nakamura","year":"2021","unstructured":"Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B et al (2021) Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50\u201375 years of age with advanced myelodysplastic syndrome. J Clin Oncol 39:3328\u20133339. https:\/\/doi.org\/10.1200\/JCO.20.03380","journal-title":"J Clin Oncol"},{"key":"6060_CR8","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"39","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D et al (2021) Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol 39:3318\u20133327. https:\/\/doi.org\/10.1200\/JCO.20.02724","journal-title":"J Clin Oncol"},{"key":"6060_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3324\/haematol.2017.168716","volume":"103","author":"C Schmid","year":"2018","unstructured":"Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A et al (2018) Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and marrow transplantation. Haematologica 103:237\u2013245. https:\/\/doi.org\/10.3324\/haematol.2017.168716","journal-title":"Haematologica"},{"key":"6060_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","volume":"21","author":"T Schroeder","year":"2015","unstructured":"Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK et al (2015) Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014A retrospective multicenter analysis from the German cooperative transplant study group. Biol Blood Marrow Transpl 21:653\u2013660. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.016","journal-title":"Biol Blood Marrow Transpl"},{"key":"6060_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bbmt.2015.07.037","volume":"22","author":"R Gui\u00e8ze","year":"2016","unstructured":"Gui\u00e8ze R, Damaj G, Pereira B, Robin M, Chevallier P, Michallet M et al (2016) Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French society of bone marrow transplantation and cell therapies. Biol Blood Marrow Transpl 22:240\u2013247. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.037","journal-title":"Biol Blood Marrow Transpl"},{"key":"6060_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3324\/haematol.2015.140996","volume":"101","author":"C Craddock","year":"2016","unstructured":"Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I et al (2016) Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 101:879\u2013883. https:\/\/doi.org\/10.3324\/haematol.2015.140996","journal-title":"Haematologica"},{"key":"6060_CR13","doi-asserted-by":"publisher","first-page":"204062072110437","DOI":"10.1177\/20406207211043748","volume":"12","author":"S Park","year":"2021","unstructured":"Park S, Kim TY, Lee JH, Lee JY, Min GJ, Park SS et al (2021) Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome. Ther Adv Hematol 12:20406207211043748. https:\/\/doi.org\/10.1177\/20406207211043748","journal-title":"Ther Adv Hematol"},{"key":"6060_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","volume":"26","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al (2012) Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 26:381\u2013389. https:\/\/doi.org\/10.1038\/leu.2011.234","journal-title":"Leukemia"},{"key":"6060_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-015-0208-3","volume":"8","author":"S Han","year":"2015","unstructured":"Han S, Kim YJ, Lee J, Jeon S, Hong T, Park GJ et al (2015) Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome. J Hematol Oncol 8:118. https:\/\/doi.org\/10.1186\/s13045-015-0208-3","journal-title":"J Hematol Oncol"},{"key":"6060_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419\u2013425. https:\/\/doi.org\/10.1182\/blood-2005-10-4149","journal-title":"Blood"},{"key":"6060_CR17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/blood.2022018604","volume":"141","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Ad\u00e8s L, Borate U et al (2023) Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood 141:2047\u20132061. https:\/\/doi.org\/10.1182\/blood.2022018604","journal-title":"Blood"},{"key":"6060_CR18","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3324\/haematol.2009.007765","volume":"94","author":"M Bornh\u00e4user","year":"2009","unstructured":"Bornh\u00e4user M, Oelschlaegel U, Platzbecker U, Bug G, Lutterbeck K, Kiehl MG et al (2009) Monitoring of donor chimerism in sorted CD34\u2009+\u2009peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 94:1613\u20131617. https:\/\/doi.org\/10.3324\/haematol.2009.007765","journal-title":"Haematologica"},{"key":"6060_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000077555","volume":"112","author":"C Thiede","year":"2004","unstructured":"Thiede C, Bornh\u00e4user M, Ehninger G (2004) Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol 112:16\u201323. https:\/\/doi.org\/10.1159\/000077555","journal-title":"Acta Haematol"},{"key":"6060_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/sj.bmt.1703162","volume":"28","author":"F Nollet","year":"2001","unstructured":"Nollet F, Billiet J, Selleslag D, Criel A (2001) Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transpl 28:511\u2013518. https:\/\/doi.org\/10.1038\/sj.bmt.1703162","journal-title":"Bone Marrow Transpl"},{"key":"6060_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/bmt.2016.295","volume":"52","author":"SA Yahng","year":"2017","unstructured":"Yahng SA, Jeon YW, Yoon JH, Shin SH, Lee SE, Choi YS et al (2017) Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome. Bone Marrow Transpl 52:522\u2013531. https:\/\/doi.org\/10.1038\/bmt.2016.295","journal-title":"Bone Marrow Transpl"},{"key":"6060_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41409-019-0695-x","volume":"55","author":"J Feliu","year":"2020","unstructured":"Feliu J, Potter V, Grimaldi F, Clay J, Floro L, Saha C et al (2020) Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI). Bone Marrow Transpl 55:562\u2013569. https:\/\/doi.org\/10.1038\/s41409-019-0695-x","journal-title":"Bone Marrow Transpl"},{"key":"6060_CR23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41409-020-01039-2","volume":"56","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C, Bergmann A, Pechtel S, Fischermanns C, Haas R, Germing U et al (2021) Wilm\u2019s tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation. Bone Marrow Transpl 56:442\u2013450. https:\/\/doi.org\/10.1038\/s41409-020-01039-2","journal-title":"Bone Marrow Transpl"},{"key":"6060_CR24","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD et al (2018) Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol 19:1668\u20131679. https:\/\/doi.org\/10.1016\/S1470-2045(18)30580-1","journal-title":"Lancet Oncol"},{"key":"6060_CR25","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.3390\/cancers12082255","volume":"12","author":"C Rautenberg","year":"2020","unstructured":"Rautenberg C, Bergmann A, Germing U, Fischermanns C, Pechtel S, Kaivers J et al (2020) Prediction of response and survival following treatment with azacitidine for relapse of acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation. Cancers 12:2255. https:\/\/doi.org\/10.3390\/cancers12082255","journal-title":"Cancers"},{"key":"6060_CR26","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.bbmt.2015.04.024","volume":"21","author":"CC Yeung","year":"2015","unstructured":"Yeung CC, Gerds AT, Fang M, Scott BL, Flowers ME, Gooley T, Deeg HJ (2015) Relapse after allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: analysis of late relapse using comparative karyotype and chromosome genome array testing. Biol Blood Marrow Transpl 21:1565\u20131575. https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.024","journal-title":"Biol Blood Marrow Transpl"},{"key":"6060_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","volume":"57","author":"C Schmid","year":"2022","unstructured":"Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M et al (2022) Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transpl 57:215\u2013223. https:\/\/doi.org\/10.1038\/s41409-021-01515-3","journal-title":"Bone Marrow Transpl"},{"key":"6060_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3324\/haematol.2019.219790","volume":"105","author":"B Dholaria","year":"2020","unstructured":"Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S et al (2020) Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica 105:47\u201358. https:\/\/doi.org\/10.3324\/haematol.2019.219790","journal-title":"Haematologica"},{"key":"6060_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41591-018-0279-0","volume":"25","author":"Y Gurovich","year":"2019","unstructured":"Gurovich Y, Hanani Y, Bar O, Nadav G, Fleischer N, Gelbman D et al (2019) Identifying facial phenotypes of genetic disorders using deep learning. Nat Med 25:60\u201364. https:\/\/doi.org\/10.1038\/s41591-018-0279-0","journal-title":"Nat Med"},{"key":"6060_CR30","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ et al (2018) Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med 379:2330\u20132341. https:\/\/doi.org\/10.1056\/NEJMoa1808777","journal-title":"N Engl J Med"},{"key":"6060_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.bbmt.2017.02.012","volume":"23","author":"T Miyamoto","year":"2017","unstructured":"Miyamoto T, Fukuda T, Nakashima M, Henzan T, Kusakabe S, Kobayashi N et al (2017) Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan marrow donor program. Biol Blood Marrow Transpl 23:938\u2013944. https:\/\/doi.org\/10.1016\/j.bbmt.2017.02.012","journal-title":"Biol Blood Marrow Transpl"},{"key":"6060_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1200\/JCO.20.01719","volume":"39","author":"C Schmid","year":"2021","unstructured":"Schmid C, Kuball J, Bug G (2021) Defining the role of donor lymphocyte infusion in high-risk hematologic malignancies. J Clin Oncol 39:397\u2013418. https:\/\/doi.org\/10.1200\/JCO.20.01719","journal-title":"J Clin Oncol"},{"key":"6060_CR33","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1182\/bloodadvances.2023010098","volume":"7","author":"E Schulz","year":"2023","unstructured":"Schulz E, Aplan PD, Freeman SD, Pavletic SZ (2023) Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes. Blood Adv 7:4381\u20134394. https:\/\/doi.org\/10.1182\/bloodadvances.2023010098","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06060-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06060-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06060-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:13:12Z","timestamp":1735866792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06060-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6060"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06060-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board (IRB) and Ethics Committee of the Catholic Medical Center, Republic of Korea (KC20RISI1045) and was conducted according to the principles of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for obtaining consent from participants did not apply to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}